GigaCloud proves the bears wrong by reporting a resilient double-digit growth profile in the EU. Read why GCT stock is ...

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...

Energy Fuels has surged nearly 400% since last April, outperforming uranium and rare earth peers. Read why I retain a hold ...

SPDR Portfolio S&P 500 High Dividend ETF (SPYD) has outperformed SPY since June last year, challenging assumptions about ...

Core-satellite portfolios balance broad index exposure with selective contrarian opportunities for potential long-term ...

Berkshire Hathaway (BRK.A) (BRK.B) stock is in focus as the company posts a decline in Q4 operating earnings amid headwinds ...

SCZ ETF review: diversification and 2025 gains vs a 0.40% expense ratio, Japan concentration and currency risk.

Verisk Analytics' recent slump aligns with an industry-wide downturn, as evidenced by similar trends in Moody's and Experian.

Explore BDCs built to overcome SaaS credit risk amid bearish sentiment. Click for more on Main Street Capital and Capital ...

Acadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE are guided to continue their strong growth trajectories. Read why ACAD stock is a buy.

New Berkshire Hathaway CEO Greg Abel vows to uphold Buffett’s stewardship and values, and flags slower insurance growth in 2025—read the latest update now.

Omnicom Group offers compelling value at under 8x earnings, with a well-covered 3.5% yield and significant upside potential.